(PGE2) has complex effects on airway tone, and the existence of four PGE2 [E-prostanoid (EP)] receptors, each with distinct signaling characteristics, has provided a possible explanation for the seemingly contradictory actions of this lipid mediator. To identify the receptors mediating the actions of PGE2 on bronchomotor tone, we examined its effects on the airways of wild-type and EP receptor-deficient mice. In conscious mice the administration of PGE2 increased airway responsiveness primarily through the EP1 receptor, although on certain genetic backgrounds a contribution of the EP3 receptor was detected. These effects of PGE2 were eliminated by pretreatment with either atropine or bupivacaine and were undetectable in anesthetized mice or in denervated tracheal rings, where only EP2-mediated relaxation of airway smooth muscle was observed. Together, our findings are consistent with a model in which PGE2 modulates airway tone by activating multiple receptors expressed on various cell populations and in which the relative contribution of these receptors might depend on the expression of modifier alleles. PGE2/EP1/EP3-induced airway constriction occurs indirectly through activation of neural pathways, whereas PGE2-induced bronchodilation results from direct activation of EP2 receptors on airway smooth muscle. This segregation of EP receptor function within the airway suggests that PGE2 analogs that selectively activate the EP2 receptor without activating the EP1/EP3 receptors might prove useful in the treatment of asthma. PGE2 receptor; bronchoconstriction; bronchodilation; knockout; nerves SHORTLY AFTER ITS DISCOVERY in the 1960s, prostaglandin E 2 (PGE 2 ) was observed to have potent relaxant effects on airway smooth muscle, making this endogenous lipid an attractive candidate drug for asthma (18, 34) . However, human studies with aerosolized PGE 2 have demonstrated inconsistent effects on airway tone, with most asthmatics showing a bronchodilator response but some developing profound bronchoconstriction requiring beta agonist rescue (6, 19) . Ex vivo studies from humans and animals have also shown that PGE 2 can both relax and constrict airway smooth muscle, a paradox explained when it was recognized that PGE 2 could act through more than one receptor (9, 20, 26) .
To identify the receptors mediating the actions of PGE2 on bronchomotor tone, we examined its effects on the airways of wild-type and EP receptor-deficient mice. In conscious mice the administration of PGE2 increased airway responsiveness primarily through the EP1 receptor, although on certain genetic backgrounds a contribution of the EP3 receptor was detected. These effects of PGE2 were eliminated by pretreatment with either atropine or bupivacaine and were undetectable in anesthetized mice or in denervated tracheal rings, where only EP2-mediated relaxation of airway smooth muscle was observed. Together, our findings are consistent with a model in which PGE2 modulates airway tone by activating multiple receptors expressed on various cell populations and in which the relative contribution of these receptors might depend on the expression of modifier alleles. PGE2/EP1/EP3-induced airway constriction occurs indirectly through activation of neural pathways, whereas PGE2-induced bronchodilation results from direct activation of EP2 receptors on airway smooth muscle. This segregation of EP receptor function within the airway suggests that PGE2 analogs that selectively activate the EP2 receptor without activating the EP1/EP3 receptors might prove useful in the treatment of asthma. PGE2 receptor; bronchoconstriction; bronchodilation; knockout; nerves SHORTLY AFTER ITS DISCOVERY in the 1960s, prostaglandin E 2 (PGE 2 ) was observed to have potent relaxant effects on airway smooth muscle, making this endogenous lipid an attractive candidate drug for asthma (18, 34) . However, human studies with aerosolized PGE 2 have demonstrated inconsistent effects on airway tone, with most asthmatics showing a bronchodilator response but some developing profound bronchoconstriction requiring beta agonist rescue (6, 19) . Ex vivo studies from humans and animals have also shown that PGE 2 can both relax and constrict airway smooth muscle, a paradox explained when it was recognized that PGE 2 could act through more than one receptor (9, 20, 26) .
Four distinct cell surface receptors for PGE 2 [E-prostanoid (EP)] have been identified and cloned, each with unique signal transduction mechanisms as a result of coupling to different G proteins (23) . Activation of one or a combination of receptors, each which may be differentially expressed on airway smooth muscle, epithelia, neurons, and immune effector cells, results in a specific physiological response. EP2 and EP4 receptors couple to G s , and activation of these receptors results in stimulation of adenylyl cyclase and increases in intracellular cAMP. Various EP3 isoforms, arising from the differential splicing of the EP3 gene, have been identified both in humans and in mice (1, 24) . Differences in the cytoplasmic domain of the EP3 receptor leads to the activation of different intracellular pathways, depending on which isoform the cell expresses (22) . In both mouse and human cells, expression of isoforms capable of coupling to G i , G q , and G s have been described (15, 24) . Activation of the EP1 receptor leads to an increase in intracellular calcium. Expression analysis has detected mRNA corresponding to all four receptors in the mouse lung (16, 36) .
Although EP receptor distribution among cells within the lung is not well established, it is clear that various airway cells can express multiple EP receptors. Thus the complexity of the integrated airway response to PGE 2 (altered bronchomotor tone) is a function of cooperativity among various EP receptors in multiple cell types in the airway. To clarify the relative contributions of each EP receptor and the integrative nature of EP receptor signaling in the airway, we examined airway reactivity in response to PGE 2 in mice deficient in each of the PGE 2 receptors using a number of different methodologies.
MATERIALS AND METHODS
Experimental animals. All studies were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals as well as the Institutional Animal Care and Use Committee guidelines of the University of North Carolina at Chapel Hill. Wild-type C57BL/6, 129X1/Sv, DBA/1, DBA/2, and BALB/c mice were purchased from Jackson Laboratories. 129/SvEv mice were purchased from Taconic. Mice deficient in the EP1, EP2, EP3, and EP4 receptors were generated and genotyped by Southern blot analysis or PCR as previously described (7, 25, 32, 35) . EP1-, EP2-, and EP3-deficient mice were backcrossed 12 generations to the C57BL/6 background. EP4Ϫ/Ϫ mice on inbred backgrounds, including C57BL/6, die from patent ductus arteriosis but survive on a mixed genetic background consisting of DBA/2, C57BL/6, and 129/Ola. A recombinant inbred strain consisting of these backgrounds has been developed to carry the EP4 mutation and EP4ϩ/ϩ controls. EP1 mice on an inbred DBA/1 background were also used for some experiments where indicated. For all experiments, mice were Ͼ8 wk old, and wild-type and receptor-deficient animals were matched for age, sex, and strain.
Measurements of airway responsiveness in conscious mice. Mice were placed in a whole body plethysmograph (Buxco Electronics, Troy, NY), and baseline measurements of enhanced pause (Penh) were obtained. Penh is a dimensionless index calculated from inspiratory pressures, expiratory pressures, and expiratory time and has been shown to correlate with direct measures of pulmonary resistance in mechanically ventilated animals (11) . Penh was then measured in response to aerosols of vehicle (10% ethanol), PGE 2 (100 g/ml), or methacholine (100 mg/ml). In some experiments, mice were treated with aerosolized 0.75% bupivacaine (Abbott Laboratories, Chicago, IL) for 10 min or an intraperitoneal injection of 10 mol/kg atropine sulfate (American Pharmaceutical Partners, Los Angeles, CA) 2 min before PGE 2 aerosols.
Measurements of airway resistance in anesthetized mice. Mice were anesthetized with 70-90 mg/kg pentobarbital sodium, tracheostomized, and mechanically ventilated at a rate of 300 breaths/min, tidal volume of 6 cc/kg, and positive end-expiratory pressure of 3-4 cmH 20 with a computercontrolled small-animal ventilator (Scireq, Montreal, Canada). Once ventilated, mice were paralyzed with 0.8 mg/kg pancuronium bromide, and we determined lung resistance by transducing airway pressures and using the equation of motion. Aerosols of PGE 2 (Cayman Chemical, Ann Arbor, MI) and methacholine (Sigma Chemical, St. Louis, MO) were delivered via nebulizer (DeVilbiss) through a side port in the ventilator circuit. Indomethacin-treated mice received an intravenous tail vein injection of 10 mg/kg indomethacin within 4 h of the experiment.
Tension development in tracheal ring preparations. Mice were euthanized by inhalation of CO 2, the trachea was rapidly excised, and serosa and connective tissue were removed. Each trachea was sectioned into 3-to 4-mm segments, rinsed, and incubated for 30 min in Ham's F-12 and DMEM (vol/vol) media containing 5,958 mg/l HEPES, 10% FBS, 584 mg/l glutamine, and 0.2g/l CaCl 2. Segments were then supported longitudinally by a Plexiglas rod with a stainless steel pin in a double-jacketed, glass organ bath perfused with 10 ml of Krebs-Henseleit solution maintained at 37°C (2, 14) . The bathing solution was continuously aerated with 5% CO 2 and 95% O 2 at a pH of 7.40-7.45 for the duration of the experiment. The upper support for the tracheal segment was secured by a silk thread loop attached to a FT03 isometric transducer (Astro-Med, West Warwick, RI), and force generation was recorded with a MP 100WS system (BIOPAC Systems). After initial stabilization in force measurements, ring tension was set to 0.5 g and maintained for 1 h. Carbachol (CCh) or PGE 2 was then added at increasing concentrations to establish dose-response curves. Concentrations were increased only when force generation responses to the previous dose had stabilized. For subsequent analysis of the relaxant effect of PGE 2 (following assessment of the dosedependent response to CCh), tissues were washed thoroughly, adjusted to the original resting tension, and contracted with the previously determined concentration of CCh producing 80% of the maximal concentration. Upon obtaining a steady-state level of tension, we added PGE 2 (0.01-10 M) to the bath progressively, and a level of steadystate tension was established for each concentration. IC50 values and maximal relaxation effect (expressed as a percentage of maximal inhibition induced by 200 M papaverine added at the end of PGE2 dose-response determination) were calculated and compared among groups. At the conclusion of each experiment, tracheal segments were blotted on a gauze pad and weighed. Force generation was calculated as milligrams of tension per milligram of tracheal ring weight.
Statistical analysis. All data are presented as means Ϯ SE. Statistical significance was assessed by the two-tailed, unpaired Student's t-test. The two-factor ANOVA with replication was used to analyze differences between groups over time from the beginning of PGE2 aerosolization through the response period.
RESULTS

Effect of PGE 2 on the airways of conscious mice.
To determine the effects of PGE 2 on the airways of conscious mice, we evaluated six different mouse strains using whole body plethysmography. Mice were exposed to aerosolized PGE 2 (100 g/ml) for 5 min following a 5-min aerosolization of 10% ethanol vehicle (Fig. 1) . A small but statistically significant increase in Penh in response to ethanol vehicle was seen in most lines tested. Variable effects of ethanol on airway tone have been reported in different species including humans (10, 13, 17, 28) . PGE 2 had no effect above that seen with vehicle alone in 129X1/Sv, 129SvEV, and DBA/2 mice. A trend toward responsiveness to PGE 2 (P ϭ 0.13) was seen in DBA/1 mice, whereas statistically significant increases in Penh above that produced by vehicle were seen in BALB/c and C57BL/6 animals.
PGE 2 -induced airway responses are diminished in EP1-and EP3-deficient mice.
To determine the receptors mediating these effects of PGE 2 , we measured airway responsiveness following PGE 2 exposure in EP receptor-deficient mice (Fig. 2) . In all cases except for EP4, we carried out the experiments using mice in which the mutant allele was introduced onto the inbred C57BL/6 genetic background. In the case of EP4 mice, a recombinant inbred strain, as well as the corresponding congenic EP4Ϫ/Ϫ line, was used. This strain allows EP4Ϫ/Ϫ animals to undergo closure of the ductus arteriosus in the absence of the receptor and thus survive to adulthood (25) . No significant differences were seen between EP2Ϫ/Ϫ or EP4Ϫ/Ϫ mice and their respective wild-type controls at any time point before, during, or following PGE 2 aerosol (Fig. 2, B and  D) . In contrast, the response to PGE 2 was significantly attenuated in EP1Ϫ/Ϫ and EP3Ϫ/Ϫ animals, suggesting that both receptors contribute to PGE 2 -induced airway responsiveness in C57BL/6 mice (Fig. 2, A and  C) . To confirm that these effects were mediated by a loss of EP1 and EP3 receptor signaling rather than by altered intrinsic contractile properties, we measured the response to methacholine in EP1Ϫ/Ϫ, EP3Ϫ/Ϫ, and wild-type control animals. No differences were observed between EP1Ϫ/Ϫ or EP3Ϫ/Ϫ mice and their respective wild-type controls following exposure to 100 mg/ml methacholine for 5 min (data not shown).
To further evaluate the role of the EP1 receptor in this response, we examined mice from the original DBA/1 line on which this mutation was generated. In contrast to our findings with C57BL/6 mice, EP1Ϫ/Ϫ mice on the DBA/1 background showed no response to PGE 2 , whereas DBA/1 wild-type control mice showed significant increases in Penh following PGE 2 exposure (Fig. 3) .
Effect of PGE 2 on lung resistance in anesthetized mice. To further evaluate the effects of PGE 2 on bronchomotor tone in vivo, we measured lung resistance before and after aerosols of PGE 2 in anesthetized, tracheostomized, mechanically ventilated mice. Surprisingly, no change in resistance was observed following exposure of the airways of C57BL/6 or DBA/1lac wild-type mice to high concentrations of PGE 2 aerosols (100 g/ml) (Fig. 4) . To ensure that the failure to observe a constrictor response was not due to opposing actions of the EP2 receptor, we repeated this experiment with EP2Ϫ/Ϫ mice. PGE 2 failed to alter baseline airway tone in this mutant mouse line as well (data not shown). Because endogenously released prostanoids may activate receptors on airway smooth muscle, po- Fig. 1 . Airway responsiveness to PGE2 among different inbred mouse strains. Airway responsiveness was measured by whole body plethysmography at baseline after a 5-min exposure to aerosolized vehicle (10% ethanol in PBS) and after a 5-min exposure to aerosolized PGE2 (100 g/ml). Data represent the mean enhanced pause (Penh) during the 5-min baseline period (open bars) and mean Penh during the 2-min period immediately following vehicle (hatched bars) or PGE2 (solid bars) aerosolization Ϯ SE, n ϭ 8 per group. *P Ͻ 0.05 compared with vehicle; ϩP Ͻ 0.05 compared with baseline. Fig. 2 . Airway responsiveness to PGE2 in PGE2 (EP) receptor-deficient mice. After a 5-min exposure to aerosolized vehicle, airway responsiveness was measured by whole body plethysmography during and after exposure to a 5-min aerosol of PGE2 (100 g/ml). Data represent mean Penh each min during (1-5) and following (6-12) PGE2 exposure Ϯ SE. F, Wild-type controls (ϩ/ϩ); E, EP-deficient mice (Ϫ/Ϫ). A: EP1ϩ/ϩ n ϭ 20, EP1Ϫ/Ϫ n ϭ 20. B: EP2ϩ/ϩ n ϭ 21, EP2Ϫ/Ϫ n ϭ 18. C: EP3ϩ/ϩ n ϭ 28, EP3Ϫ/Ϫ n ϭ 30. D: EP4ϩ/ϩ n ϭ 10, EP4Ϫ n ϭ 9. *P Ͻ 0.05; **P Ͻ 0.005. Airway responsiveness in EP1Ϫ/Ϫ and EP3Ϫ/Ϫ mice from the beginning of PGE2 aerosol until the end of the experiment was significantly different (P Ͻ 0.001) compared with their respective wild-type controls by 2-factor ANOVA. All animals were on a C57BL/6 background, except EP4Ϫ/Ϫ mice and their ϩ/ϩ controls, which were on a recombinant inbred strain.
tentially rendering them refractory to exogenously administered PGE 2 , we repeated measurements of lung resistance in response to aerosolized PGE 2 in mice pretreated with indomethacin. Again, no changes in lung resistance were observed following PGE 2 exposure (data not shown).
In contrast, the bronchoprotective actions of PGE 2 were easily measured in this system. As shown in Fig.  5 , pretreatment of wild-type mice with PGE 2 dramatically attenuated the bronchoconstrictor response to methacholine. This protective response was partially lost in mice lacking the G s -coupled EP2 receptor (Fig.  5) . Because some bronchoprotection remained in the EP2Ϫ/Ϫ animals, we hypothesized that the G s -coupled EP4 receptor may also play a role. However, methacoline-induced constriction was attenuated by PGE 2 to a similar degree in EP4Ϫ/Ϫ and ϩ/ϩ mice, suggesting that the EP4 receptor does not contribute to this brochoprotective response (data not shown).
Effect of PGE 2 on ex vivo tracheal rings. To begin to define the cell types through which PGE 2 influences bronchomotor tone, we examined its effects on isolated tracheal rings from each of the four mouse lines and the appropriate wild-type controls. In contrast to the airway response produced in conscious mice but similar to our findings in anesthetized animals, PGE 2 failed to elicit contraction of tracheal rings under spontaneous tone (Fig. 6) . This was the case even in tracheal rings from EP2Ϫ/Ϫ mice, where potential antagonism of contraction by EP2 receptor activation would be absent (data not shown). To exclude the possibility that the handling of the tissue resulted in production of PGE 2 and receptor desensitization, as well as to eliminate any spontaneous tone produced by other prostanoids, we carried out a similar series of experiments in the presence of the potent cyclooxygenase inhibitor indomethacin. Again, no contraction of the tracheal rings was observed in response to PGE 2 in concentrations ranging from 1 ϫ 10 Ϫ11 to 5 ϫ 10 Ϫ5 M (Fig. 6 ). Although no contractile effects of PGE 2 could be identified in this system, the relaxant actions of PGE 2 were easily measured in rings preconstricted by the cholinergic receptor agonist CCh and assigned in part to specific EP receptors. As shown in Fig. 7 , PGE 2 produced dose-dependent relaxation of EP1Ϫ/Ϫ, EP3Ϫ/Ϫ, and EP4Ϫ/Ϫ rings that was no different from their respective wild-type controls. Interestingly, the effectiveness of PGE 2 in relaxing the constricted airway differed between the two strains of control mice, with the C57BL/6 rings relaxing to ϳ15% and the Fig. 3 . Airway responsiveness to PGE2 in EP1 receptor-deficient mice on the DBA/1 background. After a 5-min exposure to aerosolized vehicle, airway responsiveness was measured by whole body plethysmography during and after exposure to a 5-min aerosol of PGE2 (100 g /ml). Data represent mean Penh each min during (1) (2) (3) (4) (5) and following (6-12) PGE2 exposure Ϯ SE. s, EP1ϩ/ϩ (DBA) wildtype controls; ᮀ, EP1Ϫ/Ϫ (DBA) mice. *P Ͻ 0.05; **P Ͻ 0.01; ***P Ͻ 0.005. Fig. 4 . Lung resistance (RL) following PGE2 aerosols in anesthetized mice. RL was measured in anesthetized, paralyzed, tracheostomized mice at baseline (B), following a 30-s aerosolization of vehicle (V, 10% ethanol) and 4 consecutive 30-s aerosolizations of PGE2 (P, 100 g/ml) in C57BL/6 (n ϭ 3, A) and DBA/1 (n ϭ 5, B) mice. To ensure that a constrictor response was obtainable in each animal, we gave methacholine (M, 100 mg/ml) for 30 s at the end of each experiment. *P Ͻ 0.01. Fig. 5 . Protection against methacholine-induced bronchoconstriction by PGE2 in wild-type and EP2Ϫ/Ϫ mice. RL was measured in anesthetized, paralyzed, tracheostominzed mice at baseline and following a 30-s aerosolization of methacholine (100 mg/ml). Before methacholine challenge, mice were exposed to 30 s of vehicle (open bars) or PGE2 (100 g/ml, solid bars). Data represent mean RL in each group plotted as % increase from baseline Ϯ SE. Wild type: vehicle n ϭ 7, PGE2 n ϭ 6. EP2Ϫ/Ϫ: vehicle n ϭ 10, PGE2 n ϭ 10. *P Ͻ 0.05; **P Ͻ 0.01; ***P Ͻ 0.005. recombinant inbred strain (EP4ϩ/ϩ controls) relaxing to ϳ50% of maximal CCh-induced tension, respectively. These relaxant actions of PGE 2 are unlikely to be due to activation of EP receptors on epithelial cells and subsequent production of factors by these cells, as the relaxation response persisted in strips in which the epithelia had been denuded (data not shown). Enhanced relaxation was not observed in tracheal rings lacking either EP1 or EP3 receptors, as might be expected if the relaxant actions of PGE 2 on preconstricted airways were limited by activation of a constricting EP receptor on airway smooth muscle or epithelia.
By contrast, the loss of the EP2 receptor almost completely eliminated the relaxation response induced by PGE 2 in tracheal rings (Fig. 7B) , indicating that the airway smooth muscle relaxant actions of PGE 2 are highly dependent on the EP2 receptor. A small residual relaxation response was noted in EP2Ϫ/Ϫ rings, suggesting that a second receptor may contribute modestly to PGE 2 -induced relaxation in the absence of EP2. However, when EP2 is present, a contribution of a second relaxant receptor could not be detected in rings from any of the other EP-deficient lines.
Airway responses in conscious mice are prevented by interruption of neural pathways. Because all receptors for PGE 2 are expressed on sensory neurons, we considered the possibility that the airway response to PGE 2 observed in conscious animals could be neurally mediated and, consequently, more difficult to measure in isolated tissue or anesthetized mice. Thus to determine whether the physiological changes observed in conscious mice were mediated by activation of neural pathways, we measured airway responsiveness to PGE 2 following treatment with the local anesthetic bupivacaine. As shown in Fig. 8A airway responsiveness failed to increase following PGE 2 exposure in mice pretreated with bupivacaine (P ϭ 0.2-0.8). To test the contribution of the parasympathetic nervous system to this response, we measured PGE 2 -induced airway responsiveness following pretreatment with the anticholinergic agent atropine. Similar to bupivacaine, atropine prevented increases in Penh following PGE 2 aerosols (Fig. 8B) . Together, these data suggest that PGE 2 can increase airway responsiveness in conscious mice by activating EP receptors on nerves and that this action is mediated primarily by cholinergic pathways.
DISCUSSION
Although a number of previous studies have examined the bronchodilatory effects of PGE 2 , less information is available concerning the bronchoconstrictive pathways that are in part responsible for the failure to Fig. 7 . PGE2 mediated relaxation of carbachol-contracted tracheal rings from wild-type and EP receptor-deficient mice. After contraction with carbachol, relaxation to increasing doses of PGE2 was measured, and tension was compared with maximal carbachol-induced tension. E, EP receptordeficient mice; F, wild-type controls. A: EP1, n ϭ 3 per group. B: EP2, n ϭ 5 per group. C: EP3, n ϭ 3 per group. D: EP4, n ϭ 7 per group. *P Ͻ 0.05. Rings from wild-type C57BL/6 mice with (s) and without (E) indomethacin pretreatment were exposed to increasing concentrations of PGE2, and tension developed was measured. Data represent the means Ϯ SE at each concentration, n ϭ 6 per group. At the end of each experiment, rings were challenged with carbachol (C) to ensure the capacity of each sample to mount a contractile response.
develop this lipid mediator into a useful clinical reagent. We analyzed the effects of PGE 2 on the airways of mice using three different approaches, and we provide evidence supporting a model in which the constrictive actions of PGE 2 are mediated by modulation of neural pathways that contribute to airway tone. Furthermore, we show that, unlike the bronchodilatory actions of PGE 2 , which are largely dependent on expression of the EP2 receptor (8, 30) , PGE 2 -mediated airway constriction is dependent on expression of the EP1 and EP3 receptors.
A number of clinical studies have reported that, although in the majority of asthmatics, PGE 2 produces beneficial bronchodilatory and bronchoprotective effects, a subset of patients develops profound bronchoconstriction (6, 19) . These in vivo findings, coupled with earlier in vitro studies showing a contractile effect after the addition of PGE 2 directly to excised tissue, suggest that perhaps human airways could respond in an opposing manner to this lipid (3, 4, 20, 30) . We show here that PGE 2 also can produce similar paradoxical, opposing effects on the airways of conscious mice. One interpretation of this observation is simply that airway tone is determined by the overall consequence of activation of EP receptors expressed by smooth muscle cells, where the contraction or dilation observed represents the dominance of one pathway over the other under specific physiological conditions. However, although our results support a direct dilatory action of PGE 2 on smooth muscle cells through the EP2 receptor, they are not consistent with a direct "opposing" constrictor action of PGE 2 on mouse airways. We were unable to observe any response to PGE 2 in the anesthetized, tracheostomized mouse or in excised tissue, even with high levels of PGE 2 or in mice lacking the dilatory EP2 receptor. Alternatively, we suggest that our ability to observe a response only in the conscious animal supports a model in which the constrictive actions of PGE 2 are mediated by modulation of neural pathways that contribute to airway tone. These pathways are disrupted in the excised tissue, and a number of studies have shown that the activity of neural pathways can be compromised by anesthesia. For example, it is well documented that narcotic analgesics including pentobarbital sodium can block cholinergic neurotransmission (12, 31) .
We reasoned that if the response to PGE 2 is dependent on sensory nerves, then exposing the airway to a local anesthetic before PGE 2 challenge should blunt the response. Bupivacaine blocks both sensory and motor nerves at the doses we administered, and airway responsiveness to PGE 2 was prevented by bupivacaine pretreatment. To further define the mechanism by which PGE 2 produces these physiological changes in conscious mice, we blocked cholinergic neurotransmission by pretreating animals with atropine, an antagonist of muscarinic acetycholine receptors. This action eliminated airway responsiveness to PGE 2 , implicating reflex cholinergic bronchoconstriction in this process.
Our results reveal that the EP1 and the EP3 receptors are responsible for mediating these reflex cholinergic effects of PGE 2 on the airway. This is consistent with the expression of both EP1 and EP3 by sensory nerves and the demonstrated role for both the EP1 and EP3 receptors in transmitting PGE 2 -mediated pain responses in vivo (21, 27, 32, 33) . Our results therefore suggest that the ability of PGE 2 to both constrict and dilate airways is not related to differential activation of procontractile and prorelaxant EP receptors on airway smooth muscle. Although both EP1 and EP3 receptors, when activated, can increase intracellular calcium and thus, if functioning on smooth muscle cells, could mediate bronchoconstriction, no evidence for the presence of such a pathway was obtained. Rather, we suggest a model in which the ability of PGE 2 to differentially affect the airway is the result of the actions of PGE 2 on two different physiological systems, its ability to modulate directly the activity of the airway smooth muscle via EP2, and the ability to stimulate either directly or indirectly the activity of the parasympathetic neurons of the respiratory tract via EP1/EP3. Fig. 8 . Airway responsiveness to PGE2 after bupivacaine and atropine pretreatment. A: following a 10-min exposure to aerosolized bupivacaine (0.75%) ({, n ϭ 16) or saline (}, n ϭ 16), mice were exposed to PGE2 (100 g/ml) for 5 min. Data represent mean Penh Ϯ SE each minute during (1-5) and following (6-12) PGE2 exposure. B: following an injection of atropine (10 mmol/kg ip, ‚, n ϭ 12) or saline (OE, n ϭ 8), mice were exposed to PGE2 as described above. *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001 compared with baseline. Airway responsiveness between groups in A and B from the beginning of PGE2 aerosol until the end of the experiment were significantly different (P Ͻ 0.001) by ANOVA.
Interestingly, we observed that several of the effects of PGE 2 on the airway differed among mouse strains. For example, although a constrictor response to PGE 2 was easily seen in C57BL/6, DBA/1, and BALB/c mice, it was much more difficult to detect in other mouse strains. In fact, PGE 2 had no detectable effect on the airways of 129X1/Sv mice. It is interesting to speculate that the underlying reason for this variation in the responsiveness of various mouse strains may be similar to variability seen in humans following exposure to PGE 2 aerosols. In addition to quantitative differences, the background strain of mice also influenced the PGE 2 receptors contributing to the response. Although loss of the EP1 receptor completely abolished the airway response in DBA/1 mice, loss of this receptor in C57BL/6 mice only attenuated the response. This finding can be explained by the fact that an attenuated response was seen in the EP3Ϫ/Ϫ mice on this background. These results raise the possibility that differential utilization of EP receptors might represent a fundamental difference between inbred mouse strains and contribute to the variation observed between strains in many of the physiological processes where prostaglandins play a role.
Despite the potent bronchodilatory and bronchoprotective effects of PGE 2 , this prostaglandin has never been exploited as a therapy for asthma in part because of its capacity to provoke bronchoconstriction in a subset of asthmatics. In addition, PGE aerosols are irritative to human airways, producing cough and retrosternal burning. A number of lines of evidence suggest that, similar to the action of PGE 2 that we describe here, these effects of PGE 2 are neurally mediated. First, it has been shown that PGE 2 can stimulate intrapulmonary C fibers and to a lesser extent rapidly adapting irritant receptors (5). Consistent with this observation is the activation of afferent vagal C fibers by both intravenous and endobronchial administration of PGE 2 to dogs (29) . Our study in the mouse for the first time shows that the potentially clinically beneficial actions of PGE 2 are mediated by a different PGE 2 receptor than the potentially dangerous bronconstrictive actions. If a parallel situation can be demonstrated in humans, it would suggest that EP2 receptor-specific agonists might provide the valuable bronchodilatory agent that was envisioned over twenty years ago when trials were initiated to examine the usefulness of PGE 2 for the treatment of asthma.
